{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:19:49Z","timestamp":1778566789808,"version":"3.51.4"},"reference-count":86,"publisher":"The Japanese Society for Medical Mycology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3314\/mmj.57.j77","type":"journal-article","created":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T22:38:18Z","timestamp":1464647898000},"page":"J77-J88","source":"Crossref","is-referenced-by-count":11,"title":["Invasive Aspergillosis in Hematological Patients"],"prefix":"10.3314","volume":"57","author":[{"given":"Shun-ichi","family":"Kimura","sequence":"first","affiliation":[{"name":"Division of Hematology, Saitama Medical Center, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1842","reference":[{"key":"1","unstructured":"1) Pagano L, Caira M, Candoni A, et al: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91: 1068-1075, 2006."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kontoyiannis DP, Marr KA, Park BJ, et al: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50: 1091-1100, 2010.","DOI":"10.1086\/651263"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Even C, Bastuji-Garin S, Hicheri Y, Pautas C, Botterel F, Maury S, Cabanne L, Bretagne S, Cordonnier C: Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica 96: 337-341, 2011.","DOI":"10.3324\/haematol.2010.030825"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32: 358-366, 2001.","DOI":"10.1086\/318483"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Pagano L, Caira M, Candoni A, et al: Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95: 644-650, 2010.","DOI":"10.3324\/haematol.2009.012054"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7) Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couillault G, Piard F, Vagner O, Guy H: Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19: 253-259, 2001.","DOI":"10.1200\/JCO.2001.19.1.253"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH, et al: Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44: 373-379, 2007.","DOI":"10.1086\/509917"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9) Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S: ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 47: 846-854, 2012.","DOI":"10.1038\/bmt.2011.178"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10) Miceli MH, Maertens J: Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive aspergillosis. Semin Respir Crit Care Med 36: 650-661, 2015.","DOI":"10.1055\/s-0035-1562892"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11) Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100: 4358-4366, 2002.","DOI":"10.1182\/blood-2002-05-1496"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Segal BH, Walsh TJ: Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 173: 707-717, 2006.","DOI":"10.1164\/rccm.200505-727SO"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13) Cornely OA, Aversa F, Cook P, Jones B, Michallet M, Shea T, Vallejo C: Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol 87: 289-301, 2011.","DOI":"10.1111\/j.1600-0609.2011.01682.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14) Weems JJ Jr, Davis BJ, Tablan OC, Kaufman L, Martone WJ: Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control 8: 71-75, 1987.","DOI":"10.1017\/S0195941700067114"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15) Eckmanns T, R&uuml;den H, Gastmeier P: The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 193: 1408-1418, 2006.","DOI":"10.1086\/503435"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16) Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A, Sandmaier BM, Corey L, Storb RF, Marr KA: Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 10: 494-503, 2004.","DOI":"10.1016\/j.bbmt.2004.02.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17) Kontoyiannis DP: Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant 46: 165-173, 2011.","DOI":"10.1038\/bmt.2010.256"},{"key":"17","doi-asserted-by":"crossref","unstructured":"19) Abdul Salam ZH, Karlin RB, Ling ML, Yang KS: The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am J Infect Control 38: e1-7, 2010.","DOI":"10.1016\/j.ajic.2009.09.014"},{"key":"18","doi-asserted-by":"crossref","unstructured":"20) Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, Matsuyama T, Takezako N, Miwa A, Kern W, Kami M, Akiyama H, Hirai H, Togawa A: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89: 1611-1625, 2000.","DOI":"10.1002\/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21) Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326: 845-851, 1992.","DOI":"10.1056\/NEJM199203263261301"},{"key":"20","doi-asserted-by":"crossref","unstructured":"23) Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25: 5471-5489, 2007.","DOI":"10.1200\/JCO.2007.12.3851"},{"key":"21","doi-asserted-by":"crossref","unstructured":"24) Glasmacher A, Prentice A, Gorschl&uuml;ter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21: 4615-4626, 2003.","DOI":"10.1200\/JCO.2003.04.052"},{"key":"22","doi-asserted-by":"crossref","unstructured":"25) Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359, 2007.","DOI":"10.1056\/NEJMoa061094"},{"key":"23","doi-asserted-by":"crossref","unstructured":"27) Wingard JR, Carter SL, Walsh TJ, et al: Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116: 5111-5118, 2010.","DOI":"10.1182\/blood-2010-02-268151"},{"key":"24","doi-asserted-by":"crossref","unstructured":"28) Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G: Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 155: 318-327, 2011.","DOI":"10.1111\/j.1365-2141.2011.08838.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"29) van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39: 1407-1416, 2004.","DOI":"10.1086\/422312"},{"key":"26","doi-asserted-by":"crossref","unstructured":"30) Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J: Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 18: 1509-1516, 2012.","DOI":"10.1016\/j.bbmt.2012.03.014"},{"key":"27","doi-asserted-by":"crossref","unstructured":"31) Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347, 2007.","DOI":"10.1056\/NEJMoa061098"},{"key":"28","doi-asserted-by":"crossref","unstructured":"32) Cordonnier C, Maury S, Pautas C, Basti&eacute; JN, Chehata S, Castaigne S, Kuentz M, Bretagne S, Ribaud P: Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33: 943-948, 2004.","DOI":"10.1038\/sj.bmt.1704469"},{"key":"29","doi-asserted-by":"crossref","unstructured":"33) Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH: Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 61: 734-742, 2008.","DOI":"10.1093\/jac\/dkm521"},{"key":"30","doi-asserted-by":"crossref","unstructured":"34) de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al: Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and\/or systemic fungal infection. Bone Marrow Transplant 40: 245-249, 2007.","DOI":"10.1038\/sj.bmt.1705720"},{"key":"31","doi-asserted-by":"crossref","unstructured":"35) Liu Q, Lin R, Sun J, et al: Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. Biol Blood Marrow Transplant 20: 1198-1203, 2014.","DOI":"10.1016\/j.bbmt.2014.04.016"},{"key":"32","doi-asserted-by":"crossref","unstructured":"36) Kikuchi M, Nakasone H, Mitani K, Gotoh M, Kobayashi A, Kurita N, Saito T, Sato K, Kanda Y: Retrospective assessment of secondary prophylaxis for invasive aspergillosis in neutropenic hematology patients and identification of risk factors for relapse of fungal disease. Scand J Infect Dis 45: 531-536, 2013.","DOI":"10.3109\/00365548.2013.776173"},{"key":"33","doi-asserted-by":"crossref","unstructured":"37) De Pauw B, Walsh TJ, Donnelly JP, et al: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821, 2008.","DOI":"10.1086\/588660"},{"key":"34","doi-asserted-by":"crossref","unstructured":"38) Yu VL, Muder RR, Poorsattar A: Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 81: 249-254, 1986.","DOI":"10.1016\/0002-9343(86)90259-7"},{"key":"35","doi-asserted-by":"crossref","unstructured":"39) Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP: The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 52: 1144-1155, 2011.","DOI":"10.1093\/cid\/cir122"},{"key":"36","doi-asserted-by":"crossref","unstructured":"40) Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, Klingspor L: Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57: 287-295, 2008.","DOI":"10.1099\/jmm.0.47479-0"},{"key":"37","doi-asserted-by":"crossref","unstructured":"41) Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L: Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39: 199-205, 2004.","DOI":"10.1086\/421944"},{"key":"38","doi-asserted-by":"crossref","unstructured":"42) Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O: 1, 3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46: 878-885, 2008.","DOI":"10.1086\/527382"},{"key":"39","unstructured":"43) Kami M, Tanaka Y, Kanda Y, Ogawa S, Masumoto T, Ohtomo K, Matsumura T, Saito T, Machida U, Kashima T, Hirai H: Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3) -beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 85: 745-752, 2000."},{"key":"40","doi-asserted-by":"crossref","unstructured":"44) Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, Motokura T, Hirai H, Ogawa S: Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1\u21923) -beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42: 2733-2741, 2004.","DOI":"10.1128\/JCM.42.6.2733-2741.2004"},{"key":"41","doi-asserted-by":"crossref","unstructured":"45) Koo S, Bryar JM, Page JH, Baden LR, Marty FM: Diagnostic performance of the (1\u21923) -beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 49: 1650-1659, 2009.","DOI":"10.1086\/647942"},{"key":"42","doi-asserted-by":"crossref","unstructured":"46) Yoshida K, Shoji H, Takuma T, Niki Y: Clinical viability of Fungitell, a new (1\u21923) -beta-D: -glucan measurement kit, for diagnosis of invasive fungal infection, and comparison with other kits available in Japan. J Infect Chemother 17: 473-477, 2011.","DOI":"10.1007\/s10156-010-0198-6"},{"key":"43","doi-asserted-by":"crossref","unstructured":"47) White PL, Wingard JR, Bretagne S, L&ouml;ffler J, Patterson TF, Slavin MA, Barnes RA, Pappas PG, Donnelly JP: Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis 61: 1293-1303, 2015.","DOI":"10.1093\/cid\/civ507"},{"key":"44","doi-asserted-by":"crossref","unstructured":"48) Leeflang MM, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Zhang M, Bossuyt PM, Vandenbroucke-Grauls CM: Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 12: CD007394, 2015.","DOI":"10.1002\/14651858.CD007394.pub2"},{"key":"45","doi-asserted-by":"crossref","unstructured":"49) Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Am&eacute; S, Lutz P, Dufour P, Bergerat JP, Candolfi E: Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20: 1898-1906, 2002.","DOI":"10.1200\/JCO.2002.07.004"},{"key":"46","doi-asserted-by":"crossref","unstructured":"50) Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ: Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190: 641-649, 2004.","DOI":"10.1086\/422009"},{"key":"47","doi-asserted-by":"crossref","unstructured":"51) Maertens JA, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou K, Heinen C, Cr&eacute;pin B, Van Eldere J, Tabouret M, Donnelly JP, Verweij PE: Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 44: 1329-1336, 2007.","DOI":"10.1086\/514349"},{"key":"48","doi-asserted-by":"crossref","unstructured":"52) Marr KA, Laverdiere M, Gugel A, Leisenring W: Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40: 1762-1769, 2005.","DOI":"10.1086\/429921"},{"key":"49","doi-asserted-by":"crossref","unstructured":"53) Asano-Mori Y, Kanda Y, Oshima K, et al: False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 61: 411-416, 2008.","DOI":"10.1093\/jac\/dkm463"},{"key":"50","doi-asserted-by":"crossref","unstructured":"54) Kimura S, Akahoshi Y, Nakano H, et al: False-positive Aspergillus galactomannan and its kinetics in allogeneic hematopoietic stem cell transplantation. J Infect 70: 520-540, 2015.","DOI":"10.1016\/j.jinf.2015.02.012"},{"key":"51","doi-asserted-by":"crossref","unstructured":"55) Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, Verbeken E, Verhoef G, Van Eldere J, Lagrou K: Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 49: 1688-1693, 2009.","DOI":"10.1086\/647935"},{"key":"52","doi-asserted-by":"crossref","unstructured":"56) Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52: e56-93, 2011.","DOI":"10.1093\/cid\/cir073"},{"key":"53","doi-asserted-by":"crossref","unstructured":"57) Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 86: 668-672, 1989.","DOI":"10.1016\/0002-9343(89)90441-5"},{"key":"54","doi-asserted-by":"crossref","unstructured":"58) Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340: 764-771, 1999.","DOI":"10.1056\/NEJM199903113401004"},{"key":"55","doi-asserted-by":"crossref","unstructured":"59) Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135: 412-422, 2001.","DOI":"10.7326\/0003-4819-135-6-200109180-00010"},{"key":"56","doi-asserted-by":"crossref","unstructured":"60) Walsh TJ, Pappas P, Winston DJ, et al: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346: 225-234, 2002.","DOI":"10.1056\/NEJM200201243460403"},{"key":"57","doi-asserted-by":"crossref","unstructured":"61) Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391-1402, 2004.","DOI":"10.1056\/NEJMoa040446"},{"key":"58","doi-asserted-by":"crossref","unstructured":"62) Tamura K, Urabe A, Yoshida M, Kanamaru A, Kodera Y, Okamoto S, Maesaki S, Masaoka T: Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 50: 92-100, 2009.","DOI":"10.1080\/10428190802635500"},{"key":"59","doi-asserted-by":"crossref","unstructured":"63) Park JS, Kim DH, Choi CW, Jeong SH, Choi JH, Kim K, Kim SJ, Jung CW, Yang DH, Jang JH: Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Acta Haematol 124: 92-97, 2010.","DOI":"10.1159\/000315558"},{"key":"60","doi-asserted-by":"crossref","unstructured":"64) Yamaguchi M, Kurokawa T, Ishiyama K, Aoki G, Ueda M, Matano S, Takami A, Yamazaki H, Sawazaki A, Yamauchi H, Yoshida T, Nakao S: Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol 90: 1209-1217, 2011.","DOI":"10.1007\/s00277-011-1277-1"},{"key":"61","doi-asserted-by":"crossref","unstructured":"65) Yoshida M, Tamura K, Imamura M, Niitsu Y, Sasaki T, Urabe A, Ohyashiki K, Naoe T, Kanamaru A, Tanimoto M, Masaoka T: Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders. Ann Hematol 91: 449-457, 2012.","DOI":"10.1007\/s00277-011-1316-y"},{"key":"62","doi-asserted-by":"crossref","unstructured":"66) Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dh&eacute;din N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48: 1042-1051, 2009.","DOI":"10.1086\/597395"},{"key":"63","doi-asserted-by":"crossref","unstructured":"67) Oshima K, Kanda Y, Asano-Mori Y, Nishimoto N, Arai S, Nagai S, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M.: Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 60: 350-355, 2007.","DOI":"10.1093\/jac\/dkm217"},{"key":"64","doi-asserted-by":"crossref","unstructured":"68) Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J: Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41: 1242-1250, 2005.","DOI":"10.1086\/496927"},{"key":"65","doi-asserted-by":"crossref","unstructured":"69) Morrissey CO, Chen SC, Sorrell TC, et al: Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 13: 519-528, 2013.","DOI":"10.1016\/S1473-3099(13)70076-8"},{"key":"66","doi-asserted-by":"crossref","unstructured":"70) Arvanitis M, Anagnostou T, Mylonakis E: Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis. Clin Infect Dis 61: 1263-1272, 2015.","DOI":"10.1093\/cid\/civ555"},{"key":"67","doi-asserted-by":"crossref","unstructured":"71) Portugal RD, Garnica M, Nucci M: Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 27: 3849-3754, 2009.","DOI":"10.1200\/JCO.2008.21.0856"},{"key":"68","doi-asserted-by":"crossref","unstructured":"72) Kimura S, Oshima K, Sato K, Sato M, Terasako K, Nakasone H, Kikuchi M, Okuda S, Kako S, Yamazaki R, Tanaka Y, Tanihara A, Nishida J, Kanda Y: Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 16: 1355-1361, 2010.","DOI":"10.1016\/j.bbmt.2010.04.012"},{"key":"69","doi-asserted-by":"crossref","unstructured":"73) Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360, 2008.","DOI":"10.1086\/525258"},{"key":"70","doi-asserted-by":"crossref","unstructured":"74) Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM, Schlamm HT, Donnelly JP, Pappas PG: Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis. a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 60, 713-720, 2014.","DOI":"10.1093\/cid\/ciu911"},{"key":"71","doi-asserted-by":"crossref","unstructured":"75) Cornely OA, Maertens J, Bresnik M, et al: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44: 1289-1297, 2007.","DOI":"10.1086\/514341"},{"key":"72","doi-asserted-by":"crossref","unstructured":"76) Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Dellow E, Herbrecht R, Donnelly JP: Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC\/MSG 2008 definitions of invasive mould disease. Mycoses 54: e449-455, 2011.","DOI":"10.1111\/j.1439-0507.2010.01947.x"},{"key":"73","doi-asserted-by":"crossref","unstructured":"77) Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C: Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 45: 1227-1233, 2010.","DOI":"10.1038\/bmt.2009.334"},{"key":"74","doi-asserted-by":"crossref","unstructured":"78) Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J: An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 64: 1274-1281, 2009.","DOI":"10.1093\/jac\/dkp355"},{"key":"75","doi-asserted-by":"crossref","unstructured":"79) Hiemenz JW, Raad, II, Maertens JA, Hachem RY, Saah AJ, Sable CA, Chodakewitz JA, Severino ME, Saddier P, Berman RS, Ryan DM, Dinubile MJ, Patterson TF, Denning DW, Walsh TJ: Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 29: 1387-1394, 2010.","DOI":"10.1007\/s10096-010-1013-0"},{"key":"76","doi-asserted-by":"crossref","unstructured":"80) Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53: 337-349, 2006.","DOI":"10.1016\/j.jinf.2006.03.003"},{"key":"77","doi-asserted-by":"crossref","unstructured":"81) Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdi&egrave;re M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA: Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 11: 89-93, 2009.","DOI":"10.1111\/j.1399-3062.2008.00349.x"},{"key":"78","doi-asserted-by":"crossref","unstructured":"82) Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33: e83-90, 2001.","DOI":"10.1086\/323020"},{"key":"79","doi-asserted-by":"crossref","unstructured":"83) Caillot D: Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 109: 111-118, 2003.","DOI":"10.1159\/000069281"},{"key":"80","doi-asserted-by":"crossref","unstructured":"84) Walsh TJ, Raad I, Patterson TF, et al: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44: 2-12, 2007.","DOI":"10.1086\/508774"},{"key":"81","doi-asserted-by":"crossref","unstructured":"85) Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42: 1398-1403, 2006.","DOI":"10.1086\/503425"},{"key":"82","doi-asserted-by":"crossref","unstructured":"86) Maertens JA, Raad, II, Marr KA, et al: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: 760-769, 2016.","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"83","doi-asserted-by":"crossref","unstructured":"87) Marr KA, Boeckh M, Carter RA, Kim HW, Corey L: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39: 797-802, 2004.","DOI":"10.1086\/423380"},{"key":"84","doi-asserted-by":"crossref","unstructured":"88) Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98: 292-299, 2003.","DOI":"10.1002\/cncr.11479"},{"key":"85","doi-asserted-by":"crossref","unstructured":"89) Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larch&eacute; J, Monchecourt F, Alfandari S, Mahi L: Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110: 2740-2746, 2007.","DOI":"10.1002\/cncr.23109"},{"key":"86","doi-asserted-by":"crossref","unstructured":"90) Marr KA, Schlamm HT, Herbrecht R, et al: Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162: 81-89, 2015.","DOI":"10.7326\/M13-2508"}],"container-title":["Medical Mycology Journal"],"original-title":["\u8840\u6db2\u9818\u57df\u306b\u304a\u3051\u308b\u4fb5\u8972\u6027\u30a2\u30b9\u30da\u30eb\u30ae\u30eb\u30b9\u75c7"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/2\/57_J77\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:21:50Z","timestamp":1498317710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/2\/57_J77\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.57.j77","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}